Managing adverse effects of immunotherapy.
Clin Adv Hematol Oncol
; 16(5): 364-374, 2018 May.
Article
em En
| MEDLINE
| ID: mdl-29851932
ABSTRACT
Remarkable efficacy has been achieved in a variety of cancer types by targeting immune checkpoints. The cytotoxic T-lymphocyte-associated antigen 4 inhibitor ipilimumab, the programmed death 1 inhibitors nivolumab and pembrolizumab, and the programmed death ligand 1 inhibitors atezolizumab, avelumab, and durvalumab are the agents currently approved by the US Food and Drug Administration for the treatment of certain advanced malignancies. These agents mark a departure from both standard cytotoxic chemotherapy and targeted therapy. However, they are associated with a unique set of immune-related adverse events (irAEs), which can manifest as a wide range of autoimmune phenomena. The irAEs can affect any system in the body and in rare cases are life-threatening. It is critical for the practicing medical oncologist to recognize and promptly treat any irAEs that may develop.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Regulação Neoplásica da Expressão Gênica
/
Neoplasias Hematológicas
/
Anticorpos Monoclonais Humanizados
/
Ipilimumab
/
Imunoterapia
/
Anticorpos Monoclonais
/
Antineoplásicos
Tipo de estudo:
Etiology_studies
Idioma:
En
Revista:
Clin Adv Hematol Oncol
Assunto da revista:
HEMATOLOGIA
/
NEOPLASIAS
Ano de publicação:
2018
Tipo de documento:
Article